News
The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated statistically significant ...
14m
According to a new comprehensive report from The Insight Partners, the global ovarian cancer drugs market is observing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback